Cancer Treatment Updates
June 5th, 2020As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
May 26th, 2020In an NCI study, an alternative treatment regimen called dose-adjusted EPOCH-R that is less toxic than standard dose-intensive chemotherapy was highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.
March 24th, 2020In a new study, higher daily step counts were associated with lower mortality risk from all causes. Researchers found that the number of steps taken each day, but not the intensity of the stepping, had a strong association with mortality.
March 19th, 2020Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.
March 19th, 2020A new study offers insight into genetic alterations associated with osteosarcoma, the most common bone tumor of children and adolescents, and the findings have implications for genetic testing of children with osteosarcoma and their families.
March 18th, 2020An NCI clinical trial finds the drug selumetinib improves outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors called plexiform neurofibromas, reducing pain, and improving function and overall quality of life.
March 12th, 2020The 2020 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline in the United States for all cancer sites combined. A companion study looked at Healthy People 2020 targets for four common cancers.
March 4th, 2020Testing for prostate cancer with a combined biopsy method led to more accurate diagnosis and prediction of the course of the disease in an NCI study. The method is poised to reduce the risk of prostate cancer overtreatment and undertreatment.
December 10th, 2019For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.
September 18th, 2019Nearly half of phase 3 cancer clinical trials carried out by the NCI-sponsored SWOG Cancer Research Network were associated with clinical care guidelines or new drug approvals, a study in JAMA Network Open shows.